Elekta: Interim report, May-January 2021/22
STOCKHOLM,Feb. 24,2022 -- The demand for Elekta's solutions continued to be strong in the third quarter,the fifth consecutive quarter with underlying order growth,resulting in Elekta's strongest order backlog ever. However,the global supply chain challenges remained,and revenue and margins came in lower than last year. We are fully committed to returning to revenue growth and margin expansion.
Gustaf Salford
President and CEO
Third quarter
Gross order intake amounted to SEK 4,441 M (3,954),corresponding to an 8 percent increase in constant currency.
Net sales were SEK 3,602 M (3,581),corresponding to a 3 percent decrease in constant currency
Gross margin amounted to 36.7 percent (38.7)
EBIT amounted to SEK 340 M (468),corresponding to an EBIT margin of 9.4 percent (13.1). Excluding the contribution to Elekta Foundation,EBIT was SEK 375 M,corresponding to a margin of 10.4 per-cent.
Earnings per share was SEK 0.60 (0.84) before/after dilution
Cash flow after continuous investments amounted to SEK 187 M (496)
First nine months
Gross order intake amounted to SEK 12,467 M (12,032),corresponding to a 5 percent growth in constant currency
Net sales were SEK 10,309 M (10,096),corre-sponding to a 4 percent increase in constant currency
Gross margin amounted to 37.5 percent (41.6)
EBIT amounted to SEK 1,074 M (1,361),corresponding to an EBIT margin of 10.4 percent (13.5).
Earnings per share was SEK 1.93 (2.39) before/after dilution
Cash flow after continuous investments amounted to SEK -173 M (886)
Significant events after the quarter
On 14 February,Elekta published preliminary results for the third quarter.
Group summary
Q3
First nine months
SEK M
2021/22
2020/21
Δ
2021/22
2020/21
Δ
Gross order intake
4,441
3,954
8%4
12,467
12,032
5%4
Net sales
3,602
3,581
-3%4
10,309
10,096
4%4
Gross margin
36.7%
38.7%
-2 ppts
37.5%
41.6%
-4,1 ppts
EBIT 1
340
468
-27%
1,074
1,361
-21%
EBIT margin
9.4%
13.1%
-3,6 ppts
10.4%
13.5%
-3,1 ppts
Cash flow 2
187
496
-62%
-173
886
-120%
Earnings per share,SEK 3
0.60
0.84
-29%
1.93
2.39
-19%
1Including the contribution to Elekta Foundation of SEK 35 M reported in Q3 2021/22.
2After continuous investments.
3Before/after dilution.
4Based on constant currency.
For further information,please contact:
Cecilia Ketels,Head of Investor Relations
Tel: +46 76 611 76 25,e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time
Tobias Hägglöv,CFO
Tel: +46 76107 47 99,e-mail: tobias.hagglov@elekta.com
Time zone: CET: Central European Time
This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on February 24,2022. (REGMAR)
About Elekta
As a leader in precision radiation therapy,Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable,outcome-driven and cost-efficient solutions to meet evolving patient needs,improve lives and bring hope to everyone dealing with cancer. To us,it's personal,and our global team of 4,700 employees combine passion,science,and imagination to profoundly change cancer care. We don't just build technology,we build hope. Elekta is headquartered in Stockholm,Sweden,with offices in more than 120 countries and listed on Nasdaq Stockholm. For more information,visitelekta.comor follow@Elektaon Twitter.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/elekta/r/interim-report--may-january-2021-22,c3513327
The following files are available for download:
https://mb.cision.com/Main/35/3513327/1540009.pdf
Elekta Q3 Report 21_22
https://news.cision.com/elekta/i/group-summary-q3-2021-22,c3016428
Group summary Q3 2021-22
